Brief: Prokidney Announces Alignment With The FDA On The Accelerated Approval Pathway For Rilparencel

Prokidney

15/07/2025 13:24

July 15 (Reuters) - ProKidney Corp PROK.O:

PROKIDNEY ANNOUNCES ALIGNMENT WITH THE FDA ON THE ACCELERATED APPROVAL PATHWAY FOR RILPARENCEL

PROKIDNEY CORP - FDA CONFIRMS EGFR SLOPE AS SURROGATE ENDPOINT FOR RILPARENCEL IN PATIENTS WITH CKD & TYPE 2 DIABETES

PROKIDNEY CORP - TOPLINE DATA FOR ACCELERATED APPROVAL EXPECTED IN Q2 2027

PROKIDNEY CORP - FDA CONFIRMS PHASE 3 PROACT 1 STUDY CAN BE USED FOR BOTH ACCELERATED APPROVAL & FOR FULL APPROVAL

Source text: ID:nGNX5bQsS8

Further company coverage: PROK.O

 ((Reuters.Briefs@thomsonreuters.com;))